Adrianus C M Boon
Overview
Explore the profile of Adrianus C M Boon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
3982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Darling T, Harastani H, Joshi A, Bricker T, Soudani N, Seehra K, et al.
Sci Adv
. 2024 Jul;
10(31):eadp1290.
PMID: 39083604
COVID-19 vaccines have successfully reduced severe disease and death after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nonetheless, COVID-19 vaccines are variably effective in preventing transmission and symptomatic SARS-CoV-2...
12.
Trende R, Darling T, Gan T, Wang D, Boon A
bioRxiv
. 2024 Jun;
PMID: 38915710
The transmission bottleneck, defined as the number of viruses that transmit from one host to infect another, is an important determinant of the rate of virus evolution and the level...
13.
Vanderheiden A, Hill J, Jiang X, Deppen B, Bamunuarachchi G, Soudani N, et al.
Nat Immunol
. 2024 Jun;
25(7):1158-1171.
PMID: 38902519
Up to 25% of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit postacute cognitive sequelae. Although millions of cases of coronavirus disease 2019 (COVID-19)-mediated memory dysfunction are...
14.
Bamunuarachchi G, Najera F, Aziati I, Palmer J, Biro E, Wang D, et al.
bioRxiv
. 2024 Jun;
PMID: 38895490
Bourbon virus (BRBV) is an emerging pathogen that can cause severe and fatal disease in humans. BRBV is vectored by (lone star ticks), which are widely distributed across the central,...
15.
Boon A, Bricker T, Fritch E, Leist S, Gully K, Baric R, et al.
J Virol
. 2024 Apr;
98(5):e0190323.
PMID: 38593045
Importance: SARS-CoV-2 and other emerging RNA coronaviruses are a present and future threat in causing widespread endemic and pandemic infection and disease. In this paper, we have shown that the...
16.
Boon A, Bricker T, Fritch E, Leist S, Gully K, Baric R, et al.
bioRxiv
. 2024 Feb;
PMID: 38405752
Importance: SARS-CoV-2 and other emerging RNA coronaviruses are a present and future threat in causing widespread endemic and pandemic infection and disease. In this paper, we have shown that the...
17.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
Nat Immunol
. 2024 Feb;
25(3):578.
PMID: 38360936
No abstract available.
18.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
Nat Immunol
. 2024 Feb;
25(3):537-551.
PMID: 38337035
A nasally delivered chimpanzee adenoviral-vectored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (ChAd-SARS-CoV-2-S) is currently used in India (iNCOVACC). Here, we update this vaccine by creating ChAd-SARS-CoV-2-BA.5-S, which encodes...
19.
Bricker T, Joshi A, Soudani N, Scheaffer S, Patel N, Guebre-Xabier M, et al.
J Virol
. 2024 Feb;
98(3):e0120623.
PMID: 38305154
Importance: As SARS-CoV-2 continues to evolve, there may be a need to update the vaccines to match the newly emerging variants. Here, we compared the protective efficacy of the updated...
20.
McMahan K, Wegmann F, Aid M, Sciacca M, Liu J, Hachmann N, et al.
Nature
. 2023 Dec;
626(7998):385-391.
PMID: 38096903
A limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against infection with current Omicron subvariants, although they still provide protection against severe disease. Enhanced mucosal immunity may...